I would not continue cemiplimab or pembrolizumab in the adjuvant setting since there is no current data to support this practice. However, I would consider adjuvant radiation based on the degree of pathologic response to neoadjuvant therapy. Adjuvant radiation is often considered for CSCC with certa...

This is a challenging question because, as you know, we have no randomized data to address it. I generally do not continue immune checkpoint therapy after resection of SCC skin. However, given the adjuvant data in melanoma and the high efficacy of anti-PD1 in skin SCC, I do think it is reasonable to...

First, if the cutaneous squamous cell carcinoma is not resectable, a neoadjuvant approach should be used (Brockwell et al., PMID 36686737). If a tumor looking resectable has been surgically removed but the surgery is an R1 or R2 resection, then additional treatment is needed. If the tumor is an R0 r...